
Silexion Therapeutics Corp
96
Recent developments highlight Silexion's efforts to advance its SIL204 clinical program and maintain Nasdaq listing compliance through reverse share splits and capital increases, alongside reporting financial results reflecting increased development costs.
- Silexion set a 1-for-24 reverse share split in November 2026 to regain Nasdaq compliance with minimum bid price requirements [N1].
- The company posted a wider Q2 2026 loss attributed to higher SIL204 development costs [N2].
- Silexion reported being on track with its clinical development program as of May 2026 [N3].
- The company attended the 7th Annual RNAi-Based Therapeutics Summit in January 2026, indicating ongoing engagement with the RNAi therapeutic community [N4].
- Positive preclinical data for SIL204 in lung cancer was reported in July 2025, supporting advancement towards Phase 2/3 trials [N5].
- Silexion completed preclinical studies on SIL204 for expanded KRAS-driven cancer therapies in May 2025 [N6].
- Q1 2025 financial results and key developments in RNAi cancer therapy were reported in May 2025 [N7].
- The company entered a strategic collaboration with Catalent in April 2025 to advance SIL204 development for KRAS-driven cancers [N8].
Silexion Therapeutics Corp focuses on RNA interference therapies for KRAS-driven cancers, including pancreatic and lung cancers. Its lead product candidate, SIL204, has progressed through preclinical studies and entered Phase 2/3 clinical trials. The company has reported positive efficacy and safety data in preclinical models and early clinical stages. Silexion has formed strategic partnerships, notably with Catalent, to support development and manufacturing. The company has undertaken multiple financing rounds and reverse share splits to support operations and maintain Nasdaq listing compliance. As of the latest SEC filings, Silexion holds sufficient liquidity to fund near-term operations but continues to report net losses consistent with clinical-stage biotech companies.
Silexion Therapeutics Corp is a clinical-stage biotech company developing RNAi therapies targeting KRAS-driven cancers, notably pancreatic and lung cancers, with its lead candidate SIL204 in Phase 2/3 trials. The company has reported positive preclinical and early clinical data supporting SIL204's development and has entered strategic collaborations to advance its pipeline. Financially, as of September 30, 2026, Silexion held $4.76 million in cash with a current ratio of 1.66, but reported a net loss of $2.53 million for the quarter. The company is actively managing Nasdaq listing compliance through reverse share splits and authorized share capital increases. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Silexion's advancement of SIL204 into Phase 2/3 trials with positive preclinical and early clinical data supports its potential as a novel RNAi therapy for KRAS-driven cancers. Strategic collaborations and successful financing rounds provide resources to progress development. Regulatory clearances for clinical trials and ongoing data readouts could enhance visibility and validation of its therapeutic approach.
Silexion faces risks typical of clinical-stage biotech companies, including clinical trial uncertainties, regulatory hurdles, and the need for continuous financing. The company is currently addressing Nasdaq listing compliance challenges, which could impact liquidity and investor confidence. Failure to maintain sufficient authorized share capital or to comply with listing standards could adversely affect operations and capital raising ability.
Silexion's moat lies in its proprietary RNAi technology targeting KRAS-driven cancers, a challenging and high-need oncology segment with limited effective therapies. Its lead candidate SIL204 has demonstrated positive preclinical and early clinical data, supported by strategic collaborations that enhance development capabilities. The company's focus on KRAS mutations, a common oncogenic driver, positions it in a niche with significant scientific and clinical barriers to entry, potentially providing competitive differentiation if clinical development advances successfully.
• Nasdaq Listing Compliance Risk: Silexion is subject to Nasdaq minimum shareholders' equity and minimum bid price requirements. Failure to maintain compliance, despite recent reverse share splits and capital increases, could lead to delisting, adversely affecting liquidity and capital access.
• Clinical Development Risk: Silexion's lead candidate SIL204 is in Phase 2/3 trials. Clinical trial outcomes are uncertain and may not demonstrate safety or efficacy sufficient for regulatory approval.
• Financing Risk: The company relies on equity financing to fund operations. Limited authorized share capital and shareholder approval requirements pose risks to timely capital raising.
• Operational Risk: As a clinical-stage company, Silexion incurs ongoing losses and must manage operational expenses carefully to sustain development activities.
Business trends: Advancement of SIL204 RNAi therapy in KRAS-driven cancers with ongoing clinical trials and strategic collaborations.
Execution milestones: Completion of preclinical studies, initiation and progression of Phase 2/3 trials, and capital raises including authorized share increases.
Key risks: Nasdaq listing compliance challenges, clinical trial uncertainties, financing constraints, and operational sustainability.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies targeting KRAS-driven cancers, including pancreatic and lung cancers.
- The company is advancing its lead product candidate SIL204, which is in Phase 2/3 clinical trials for pancreatic cancer.
- Silexion has reported positive preclinical data for SIL204 in lung cancer and pancreatic cancer models, supporting its clinical development.
- The company entered a strategic collaboration with Catalent to advance SIL204 development for KRAS-driven cancers.
- Silexion has completed toxicology and key preclinical studies for SIL204, enabling progression to clinical trials.
- The company has conducted multiple rounds of financing, including warrant exercises and private placements, to fund SIL204 development and corporate operations.
- Silexion has executed reverse share splits (1-for-9, 1-for-15, and 1-for-24) to maintain Nasdaq listing compliance.
- As of September 30, 2026, Silexion reported cash and cash equivalents of approximately $4.76 million and current assets of $6.11 million, with current liabilities of $3.68 million, resulting in a current ratio of 1.66 and a cash ratio of 1.29, indicating liquidity above short-term obligations.
- The company reported a net loss of $2.53 million for the quarter ended September 30, 2026, with basic and diluted EPS of $13.7 per share (likely reflecting share count adjustments).
- Silexion is currently addressing Nasdaq compliance issues related to minimum shareholders' equity and minimum bid price requirements, including a recent 1-for-24 reverse share split to regain compliance.
- The company’s shareholders approved an increase in authorized share capital in October 2026 after prior unsuccessful attempts, which is critical for future financing activities.
- Silexion maintains disclosure controls and procedures and has reported no material changes affecting internal control over financial reporting as of December 31, 2025.
- The company is not a large accelerated filer and is classified as an emerging growth company.
- Silexion’s continued Nasdaq listing is subject to a Nasdaq hearings panel decision, with risks of delisting if compliance is not maintained.
Generated 2026-11-13
- S1 | 2026-05-19 | 10-K/A
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-09 | www.nasdaq.com | Silexion Sets 1-For-24 Reverse Share Split To Regain Nasdaq Compliance | https://www.nasdaq.com/articles/silexion-sets-1-24-reverse-share-split-regain-nasdaq-compliance
- N2 | 2026-09-04 | www.nasdaq.com | Silexion Posts Wider Q2 Loss On Higher SIL-204 Development Costs | https://www.nasdaq.com/articles/silexion-posts-wider-q2-loss-higher-sil-204-development-costs
- N3 | 2026-05-21 | www.nasdaq.com | SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX | https://www.nasdaq.com/articles/slxn-track-imvt-hits-new-high-ctev-eyes-blockbuster-revenue-big-day-ahead-bdtx
- N4 | 2026-01-21 | www.globenewswire.com | Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit | https://www.globenewswire.com/news-release/2026/01/21/3222785/0/en/Silexion-Therapeutics-to-Attend-7th-Annual-RNAi-Based-Therapeutics-Summit.html
- N5 | 2025-07-09 | www.nasdaq.com | Silexion Therapeutics Corp. Reports Positive Preclinical Data for SIL204 in Lung Cancer, Advancing Towards Phase 2/3 Clinical Trial | https://www.nasdaq.com/articles/silexion-therapeutics-corp-reports-positive-preclinical-data-sil204-lung-cancer-advancing
- N6 | 2025-05-21 | www.nasdaq.com | Silexion Therapeutics Completes Preclinical Study on SIL204 for Expanded KRAS-Driven Cancer Therapies | https://www.nasdaq.com/articles/silexion-therapeutics-completes-preclinical-study-sil204-expanded-kras-driven-cancer
- N7 | 2025-05-13 | www.nasdaq.com | Silexion Therapeutics Reports Q1 2025 Financial Results and Key Developments in RNAi Cancer Therapy | https://www.nasdaq.com/articles/silexion-therapeutics-reports-q1-2025-financial-results-and-key-developments-rnai-cancer
- N8 | 2025-04-23 | www.nasdaq.com | Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers | https://www.nasdaq.com/articles/silexion-therapeutics-enters-strategic-collaboration-catalent-advance-sil204-development
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


